PE20081406A1 - Composiciones farmaceuticas de flunixina - Google Patents
Composiciones farmaceuticas de flunixinaInfo
- Publication number
- PE20081406A1 PE20081406A1 PE2007001807A PE2007001807A PE20081406A1 PE 20081406 A1 PE20081406 A1 PE 20081406A1 PE 2007001807 A PE2007001807 A PE 2007001807A PE 2007001807 A PE2007001807 A PE 2007001807A PE 20081406 A1 PE20081406 A1 PE 20081406A1
- Authority
- PE
- Peru
- Prior art keywords
- improver
- flunixin
- pharmaceutical compositions
- primary
- penetration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87090706P | 2006-12-20 | 2006-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081406A1 true PE20081406A1 (es) | 2008-10-17 |
Family
ID=39262615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001807A PE20081406A1 (es) | 2006-12-20 | 2007-12-14 | Composiciones farmaceuticas de flunixina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9006272B2 (enExample) |
| EP (1) | EP2120860B1 (enExample) |
| JP (1) | JP5377326B2 (enExample) |
| KR (1) | KR20090091328A (enExample) |
| CN (2) | CN101588789B (enExample) |
| AR (1) | AR064425A1 (enExample) |
| AU (1) | AU2007339312B2 (enExample) |
| BR (1) | BRPI0720500B1 (enExample) |
| CA (1) | CA2672964C (enExample) |
| CL (1) | CL2007003711A1 (enExample) |
| CO (1) | CO6190598A2 (enExample) |
| ES (1) | ES2714550T3 (enExample) |
| MX (1) | MX2009006893A (enExample) |
| NZ (1) | NZ598554A (enExample) |
| PE (1) | PE20081406A1 (enExample) |
| RU (1) | RU2466715C2 (enExample) |
| TW (1) | TWI350182B (enExample) |
| WO (1) | WO2008082507A2 (enExample) |
| ZA (1) | ZA200904329B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2738970A1 (en) * | 2008-10-31 | 2010-05-06 | Moberg Derma Ab | Topical composition comprising a combination of at least two penetration enhancing agents |
| CA2828086C (en) | 2010-03-10 | 2018-07-31 | Nuvo Research Inc. | Foamable formulation |
| WO2012022837A1 (en) * | 2010-08-16 | 2012-02-23 | Helsingin Yliopisto | Transdermal compositions |
| WO2012043701A1 (ja) * | 2010-09-30 | 2012-04-05 | 富山化学工業株式会社 | 経皮吸収製剤 |
| CN114903848A (zh) * | 2013-02-27 | 2022-08-16 | 阿根塔创新有限公司 | 透皮制剂 |
| CN105769827B (zh) * | 2016-03-09 | 2018-07-17 | 金陵科技学院 | 用于动物清热镇痛氟尼辛葡甲胺涂膜剂及其制备方法 |
| KR20200065711A (ko) | 2018-11-30 | 2020-06-09 | 한원경 | 동물 피부질환 개선용 조성물 |
| WO2021010843A1 (en) | 2019-07-16 | 2021-01-21 | Donaghys Limited | Transdermal solvent system and methods of use |
| WO2021045870A1 (en) * | 2019-09-06 | 2021-03-11 | Iowa State University Research Foundation, Inc. | Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease |
| JP7846689B2 (ja) * | 2020-11-25 | 2026-04-15 | インターベット インターナショナル ベー． フェー． | フルニキシンを口腔投与することによる疼痛の治療方法 |
| WO2022238965A1 (en) * | 2021-05-12 | 2022-11-17 | Argenta Innovation Limited | Veterinary transdermal formulation |
| CN114404360B (zh) * | 2021-12-16 | 2023-03-28 | 江西益昕葆生物科技有限公司 | 一种氟尼辛葡甲胺注射液的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63225316A (ja) * | 1986-10-21 | 1988-09-20 | Nitto Electric Ind Co Ltd | 外皮投与用組成物 |
| JPH11222443A (ja) * | 1997-11-11 | 1999-08-17 | Saitama Daiichi Seiyaku Kk | 経皮吸収促進組成物および経皮吸収製剤 |
| AU1780101A (en) | 1999-11-19 | 2001-05-30 | Xel Herbaceuticals | Transdermal delivery system for alkaloids of aconitum species |
| JP4865958B2 (ja) * | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
| US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
| CA2530407A1 (en) * | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Penetration enhancer combinations for transdermal delivery |
| JP2007500691A (ja) | 2003-07-31 | 2007-01-18 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗炎症剤の分散性製剤 |
| DE10358525A1 (de) * | 2003-12-13 | 2005-07-07 | Bayer Healthcare Ag | Endoparasitizide Mittel zur topischen Applikation |
| US7618651B2 (en) * | 2004-06-24 | 2009-11-17 | Idexx Laboratories | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
| CA2573412A1 (en) * | 2004-07-19 | 2006-02-02 | Warner-Lambert Company Llc | Formulation for stimulating hair growth |
| AU2005284422A1 (en) * | 2004-09-16 | 2006-03-23 | Bayer Healthcare Ag | Dermally applicable formulations for treating skin diseases in animals |
| WO2007061739A2 (en) * | 2005-11-21 | 2007-05-31 | Schering-Plough Ltd. | Pharmaceutical compositions comprising buprenorphine |
-
2007
- 2007-12-14 PE PE2007001807A patent/PE20081406A1/es not_active Application Discontinuation
- 2007-12-18 RU RU2009127500/15A patent/RU2466715C2/ru active
- 2007-12-18 KR KR1020097014552A patent/KR20090091328A/ko not_active Ceased
- 2007-12-18 MX MX2009006893A patent/MX2009006893A/es active IP Right Grant
- 2007-12-18 NZ NZ59855407A patent/NZ598554A/xx unknown
- 2007-12-18 EP EP07867799.4A patent/EP2120860B1/en active Active
- 2007-12-18 AR ARP070105702 patent/AR064425A1/es not_active Application Discontinuation
- 2007-12-18 WO PCT/US2007/025808 patent/WO2008082507A2/en not_active Ceased
- 2007-12-18 CN CN2007800470359A patent/CN101588789B/zh active Active
- 2007-12-18 JP JP2009542867A patent/JP5377326B2/ja active Active
- 2007-12-18 AU AU2007339312A patent/AU2007339312B2/en active Active
- 2007-12-18 US US11/959,185 patent/US9006272B2/en active Active
- 2007-12-18 ES ES07867799T patent/ES2714550T3/es active Active
- 2007-12-18 CN CN201310549264.8A patent/CN103690471B/zh active Active
- 2007-12-18 BR BRPI0720500A patent/BRPI0720500B1/pt active IP Right Grant
- 2007-12-18 CA CA2672964A patent/CA2672964C/en active Active
- 2007-12-19 TW TW096148778A patent/TWI350182B/zh not_active IP Right Cessation
- 2007-12-19 CL CL2007003711A patent/CL2007003711A1/es unknown
-
2009
- 2009-06-17 CO CO09062884A patent/CO6190598A2/es not_active Application Discontinuation
- 2009-06-19 ZA ZA200904329A patent/ZA200904329B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200833367A (en) | 2008-08-16 |
| AU2007339312A1 (en) | 2008-07-10 |
| CA2672964A1 (en) | 2008-07-10 |
| RU2009127500A (ru) | 2011-01-27 |
| CA2672964C (en) | 2018-04-03 |
| KR20090091328A (ko) | 2009-08-27 |
| CL2007003711A1 (es) | 2008-07-25 |
| CO6190598A2 (es) | 2010-08-19 |
| RU2466715C2 (ru) | 2012-11-20 |
| CN103690471B (zh) | 2015-11-18 |
| NZ598554A (en) | 2013-08-30 |
| EP2120860A2 (en) | 2009-11-25 |
| WO2008082507A3 (en) | 2009-03-19 |
| US20080153885A1 (en) | 2008-06-26 |
| TWI350182B (en) | 2011-10-11 |
| JP2010513500A (ja) | 2010-04-30 |
| BRPI0720500A8 (pt) | 2015-12-29 |
| MX2009006893A (es) | 2009-07-03 |
| ZA200904329B (en) | 2010-05-26 |
| ES2714550T3 (es) | 2019-05-29 |
| BRPI0720500B1 (pt) | 2019-01-02 |
| CN103690471A (zh) | 2014-04-02 |
| US9006272B2 (en) | 2015-04-14 |
| AU2007339312B2 (en) | 2013-06-06 |
| WO2008082507A2 (en) | 2008-07-10 |
| JP5377326B2 (ja) | 2013-12-25 |
| CN101588789A (zh) | 2009-11-25 |
| AR064425A1 (es) | 2009-04-01 |
| BRPI0720500A2 (pt) | 2014-02-04 |
| CN101588789B (zh) | 2013-12-11 |
| EP2120860B1 (en) | 2019-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116415A2 (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas | |
| BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
| MX2020001395A (es) | Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central. | |
| CO6311008A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ | |
| BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| DOP2010000114A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
| UY32761A (es) | Preparaciones termoestables y preparaciones insulinicas estables a las vibraciones | |
| WO2008057930A3 (en) | Methods of treating neuropathic pain with retinoic acid receptor agonists | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| BR112012015433B8 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
| CL2011000144A1 (es) | Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros. | |
| AR064425A1 (es) | Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| WO2013049365A3 (en) | Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives | |
| AR072685A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
| AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
| BR112012015437A2 (pt) | composição tópica substancialmente anidra de armazenamento estável | |
| NI201000189A (es) | Formulación de medicamento sólido con liberación retardadas. | |
| BR112015020707A2 (pt) | formulações transdermicas | |
| BR112014016661A2 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
| PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados | |
| CL2008001563A1 (es) | Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras. | |
| BR112013031146A2 (pt) | liberação direcionada de compostos retinóides para as glândulas sebáceas | |
| ECSP10010183A (es) | Producto de dispersión sólida de drogas basadas en n-aril-urea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |